
    
      This is a single-arm,multicenter Phase 2 study to evaluate the efficacy and safety of the
      CAR-T for recurrent or refractory acute non T lymphocyte leukemia.The study will be conducted
      using a phase I/II design.The study will have the following sequential phases:Part A
      (screening leukapheresis, cell product preparation, and cytoreductive chemotherapy) and Part
      B (treatment and follow-up). The follow-up period for each participant is approximately 35
      months after the final CAR-T infusion. The total duration of the study is expected to be
      approximately 3 years. A total of 24 patients may be enrolled over a period of 3 years.
    
  